392 related articles for article (PubMed ID: 31836698)
1. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.
Eisele L; Dürig J; Hüttmann A; Dührsen U; Assert R; Bokhof B; Erbel R; Mann K; Jöckel KH; Moebus S;
Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method.
Vachon CM; Murray J; Allmer C; Larson D; Norman AD; Sinnwell JP; Dispenzieri A; Kleinstern G; Visram A; Kyle RA; Rajkumar SV; Slager SL; Kumar SK; Murray DL
Blood Adv; 2022 Jun; 6(12):3746-3750. PubMed ID: 35316833
[TBL] [Abstract][Full Text] [Related]
6. Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima.
Fujimura K; Sugiyama A; Akita T; Ohisa M; Nagashima S; Katayama K; Maeda R; Tanaka J
Int J Hematol; 2021 Apr; 113(4):576-585. PubMed ID: 33389658
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
8. Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.
Landgren O; Zeig-Owens R; Giricz O; Goldfarb D; Murata K; Thoren K; Ramanathan L; Hultcrantz M; Dogan A; Nwankwo G; Steidl U; Pradhan K; Hall CB; Cohen HW; Jaber N; Schwartz T; Crowley L; Crane M; Irby S; Webber MP; Verma A; Prezant DJ
JAMA Oncol; 2018 Jun; 4(6):821-827. PubMed ID: 29710195
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S
Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794
[TBL] [Abstract][Full Text] [Related]
10. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV; Murray DL; Kyle RA
Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
[TBL] [Abstract][Full Text] [Related]
11. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.
Kumar S; Larson DR; Dispenzieri A; Therneau TM; Murray DL; Leif Bergsagel P; Kyle RA; Vincent Rajkumar S
Blood Cancer J; 2019 May; 9(6):49. PubMed ID: 31101803
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men.
Cicero KI; Joffe M; Patel M; Chiuzan C; Pentz A; Ruff P; Lentzsch S; Leng S; Jacobson JS; Rebbeck TR; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2192-2198. PubMed ID: 36126958
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
15. Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.
Mehra N; Gopisetty G; Subramani J; Dhanasekar S; Rajamanickam A; Perumal Kalaiyarasi J; Karunakaran P; Kannan K; Rajaraman S; Rajkumar T
Ann Clin Biochem; 2023 Sep; 60(5):339-348. PubMed ID: 37158306
[TBL] [Abstract][Full Text] [Related]
16. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
18. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.
Therneau TM; Kyle RA; Melton LJ; Larson DR; Benson JT; Colby CL; Dispenzieri A; Kumar S; Katzmann JA; Cerhan JR; Rajkumar SV
Mayo Clin Proc; 2012 Nov; 87(11):1071-9. PubMed ID: 22883742
[TBL] [Abstract][Full Text] [Related]
19. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
Kleinstern G; Larson DR; Allmer C; Norman AD; Muntifering G; Sinnwell J; Visram A; Rajkumar V; Dispenzieri A; Kyle RA; Slager SL; Kumar S; Vachon CM
Blood Cancer J; 2022 Apr; 12(4):67. PubMed ID: 35440099
[TBL] [Abstract][Full Text] [Related]
20. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]